Overview

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Metformin